Senator Hawley Introduces Controversial Bill to Withdraw Abortion Drug Approval

Senator Josh Hawley's Legislative Efforts to Withdraw Mifepristone Approval

On March 11, 2026, Senator Josh Hawley called a press conference to spotlight a significant bill regarding the controversial abortion drug, mifepristone. The bill aims to expedite a process that critics believe the Food and Drug Administration (FDA) has been slow to manage regarding the drug's approval and availability. By proposing this legislation, Hawley seeks to withdraw the approval of mifepristone, thus removing it from the market entirely. Moreover, this legislative move will empower women who feel harmed by the FDA's insufficient oversight to pursue legal action in ventures to obtain compensation.

Tony Perkins, President of the Family Research Council (FRC), voiced strong support for Hawley's initiative. He emphasized the necessity for Congress to intervene if the FDA fails to regulate mifepristone adequately. Perkins denounced the current administration's policies, which he argues allow the abortion industry to operate like any other commercial enterprise, sending abortion drugs to individuals' homes nationwide—even in states that have enacted laws to protect unborn life. Perkins claims that these policies have led to alarming increases in the number of unborn children being killed, contrary to the decreasing trends anticipated after the Roe v. Wade decision was overturned.

Mary Szoch, who directs the FRC's Center for Human Dignity, further delineated her concerns about mifepristone, describing it as distinct from other FDA-approved medications. According to Szoch, rather than enhancing health, mifepristone is intended to terminate pregnancies. She criticized the approval process of the drug as politically motivated, lamenting that insufficient safety tests were conducted prior to its authorization. As a result, she highlights the painful outcomes women experience, facing tough decisions during distressing circumstances as they grapple with grief.

Particularly alarming, Szoch points out that recent studies indicate over 10% of women who utilize mifepristone face severe complications, casting even more doubt on the FDA's decision-making process concerning the drug's safety. Given this distressing data, the call for the bill’s passage grows louder, with advocates arguing that the FDA must adopt a more rigorous review process.

FRC has also compiled resources illustrating the timeline of mifepristone's controversial history and detailing the adverse effects linked to its usage. Supporters of the bill urge the public to educate themselves on these issues, as the ramifications of such legislative actions and FDA decisions can have widespread societal impact.

The introduction of this bill by Senator Hawley is poised to ignite a fervent debate surrounding abortion rights, pharmaceutical regulation, and women's health. As the legislative process unfolds, stakeholders across the country will undoubtedly rally for their positions—whether in support of or against Hawley’s proposed changes. With emotions running high on both sides, this issue emphasizes the intertwining nature of law, medicine, and personal rights that define contemporary American discourse on reproductive health. Advocates and opponents alike will carefully watch each step of this legislative journey, as its outcomes hold the potential to reshape the landscape for abortion access in the U.S.